Please assess the completion status of the following clinical trial:

Trial Title: Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 65 years~* Meet 1984 NewYork modified criteria for AS~* BASDAI≥4 or ASDAS score ≥ 2.1~* CRP\>6 mg/L or ESR\>28 mm/h~* Syndesmophyte quantity ≥2 and \<16 of spine~* Sexually active women of childbearing potential must agree and commit to use a medically accepted form of contraception~* No active or latent tuberculosis infection.~Exclusion Criteria:~* Pregnant or breastfeeding women~* current or previous history of psoriasis or inflammatory bowel disease.~* infection with clinical significance within 24 weeks before screening~* receipt any bio-agents treatment within 12 weeks before screening~* corticosteroids intra-articular injections in last 3 months before the trial~* Significant concurrent medical events including: Gastrointestinal ulcer, myocardial infarction within 12 months before the screening visit, unstable angina pectoris, congestive heart failure.~* Alcohol and drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- celebrex (Type: ACTIVE_COMPARATOR): celebrex capsule, 0.2 gram bid, 52 weeks
- Enbrel (Type: ACTIVE_COMPARATOR): etanercept injection, 25mg per injection, 50mg/week, 52 weeks
- Enbrel plus Celebrex (Type: ACTIVE_COMPARATOR): 50mg/week Enbrel by hypodermic injection plus Celebrex 0.2 gram bid, 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).